Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.


Journal

Blood cancer discovery
ISSN: 2643-3249
Titre abrégé: Blood Cancer Discov
Pays: United States
ID NLM: 101764786

Informations de publication

Date de publication:
07 2021
Historique:
entrez: 14 7 2021
pubmed: 15 7 2021
medline: 15 3 2022
Statut: ppublish

Résumé

Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple myeloma (MM) cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output

Identifiants

pubmed: 34258103
doi: 10.1158/2643-3230.BCD-20-0108
pmc: PMC8265280
mid: NIHMS1688764
pii: 2643-3230.BCD-20-0108
doi:

Substances chimiques

MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
KDM5A protein, human EC 1.14.11.-
Retinoblastoma-Binding Protein 2 EC 1.14.11.27
Cyclin-Dependent Kinase 9 EC 2.7.11.22
Cyclin-Dependent Kinases EC 2.7.11.22
RNA Polymerase II EC 2.7.7.-
Lysine K3Z4F929H6
Cyclin-Dependent Kinase-Activating Kinase EC 2.7.11.22
CDK7 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-387

Subventions

Organisme : NCI NIH HHS
ID : K08 CA245251
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100707
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233601
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA236754
Pays : United States

Déclaration de conflit d'intérêts

DECLARATION OF INTERESTS J.Q. is scientific co-founder and consultant of Epiphanes. Other authors declare no potential conflicts of interest.

Références

Nat Chem Biol. 2016 Jul;12(7):539-45
pubmed: 27214403
Nature. 2016 Sep 22;537(7621):548-552
pubmed: 27626377
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Genes Dev. 2019 Dec 1;33(23-24):1718-1738
pubmed: 31727771
Cell. 2011 May 27;145(5):787-99
pubmed: 21620140
J Biol Chem. 2014 Oct 17;289(42):28956-70
pubmed: 25190814
Mol Cell Biol. 2009 Mar;29(6):1401-10
pubmed: 19114561
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5367-72
pubmed: 18391197
Cell. 2012 Oct 26;151(3):476-82
pubmed: 23101621
Nature. 2009 Jun 11;459(7248):847-51
pubmed: 19430464
Genes Dev. 2004 Nov 15;18(22):2747-63
pubmed: 15545632
Cell. 2012 Sep 28;151(1):68-79
pubmed: 23021216
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cell Rep. 2014 Mar 13;6(5):868-77
pubmed: 24582965
Leukemia. 2011 Jun;25(6):1026-35
pubmed: 21468039
Nucleic Acids Res. 2012 Oct;40(19):9493-505
pubmed: 22904080
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Genes Dev. 2020 Apr 1;34(7-8):465-488
pubmed: 32238450
Genes Dev. 2018 Oct 1;32(19-20):1303-1308
pubmed: 30254109
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Nucleic Acids Res. 2017 Feb 28;45(4):1743-1759
pubmed: 27899593
Cell. 2007 Mar 23;128(6):1063-76
pubmed: 17320161
Cell Chem Biol. 2017 Mar 16;24(3):371-380
pubmed: 28262558
Cancer Res. 2013 Aug 1;73(15):4711-21
pubmed: 23722541
Leukemia. 2018 Jun;32(6):1295-1306
pubmed: 29467490
Trends Cancer. 2017 Oct;3(10):713-725
pubmed: 28958389
Cancer Discov. 2015 Oct;5(10):1024-39
pubmed: 26382145
Nat Rev Genet. 2006 Sep;7(9):715-27
pubmed: 16983801
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Cell Rep. 2015 Dec 15;13(10):2219-31
pubmed: 26673323
J Biol Chem. 2001 Jul 27;276(30):28402-12
pubmed: 11358960
EMBO Rep. 2018 Dec;19(12):
pubmed: 30413482
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Cancer Cell. 2008 Feb;13(2):167-80
pubmed: 18242516
Leukemia. 2017 Dec;31(12):2670-2677
pubmed: 28490812
Nat Chem Biol. 2016 Jul;12(7):531-8
pubmed: 27214401
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18499-504
pubmed: 23093672
Science. 2011 Sep 30;333(6051):1881-5
pubmed: 21960634
Blood. 2006 Sep 15;108(6):2020-8
pubmed: 16728703
Cell. 2013 Feb 28;152(5):1021-36
pubmed: 23452851
Cell. 2012 Sep 28;151(1):56-67
pubmed: 23021215
Nat Cancer. 2020 Feb;1(2):235-248
pubmed: 32613204
Nucleic Acids Res. 2015 Mar 31;43(6):3068-78
pubmed: 25735750
J Cell Biol. 2017 Jul 3;216(7):1959-1974
pubmed: 28572115
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Nat Genet. 2018 Sep;50(9):1240-1246
pubmed: 30127528
Mol Cell Biol. 2012 May;32(9):1633-44
pubmed: 22371483
Nat Struct Mol Biol. 2008 Apr;15(4):419-21
pubmed: 18270511
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9
pubmed: 17093053
Blood Cancer J. 2018 Aug 22;8(9):83
pubmed: 30190472
Cell. 2007 Mar 9;128(5):889-900
pubmed: 17320163
Nat Genet. 2018 Apr;50(4):515-523
pubmed: 29379199
Nat Biotechnol. 2014 Jan;32(1):92-6
pubmed: 24336317
Blood. 2012 Sep 20;120(12):2450-3
pubmed: 22806891
J Biol Chem. 2016 Apr 1;291(14):7313-24
pubmed: 26841866
Mol Cell. 2007 Mar 23;25(6):801-12
pubmed: 17363312
Nature. 2014 Jul 31;511(7511):616-20
pubmed: 25043025
Cell. 2007 Oct 5;131(1):58-69
pubmed: 17884155
Mol Cell. 2020 Jun 18;78(6):1086-1095
pubmed: 32407673
Mol Cell. 2005 Jun 10;18(6):623-35
pubmed: 15949438
Mol Cell Biol. 2013 Dec;33(24):4793-810
pubmed: 24100015
Nat Cell Biol. 2006 Jul;8(7):764-70
pubmed: 16767079
Cell Rep. 2014 Nov 6;9(3):1163-70
pubmed: 25437568
Blood Cancer Discov. 2020 Jul;1(1):68-81
pubmed: 32954360

Auteurs

Hiroto Ohguchi (H)

Division of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.

Paul M C Park (PMC)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Tingjian Wang (T)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Berkley E Gryder (BE)

Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio.

Daisuke Ogiya (D)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Keiji Kurata (K)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Xiaofeng Zhang (X)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Deyao Li (D)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Chengkui Pei (C)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Takeshi Masuda (T)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Catrine Johansson (C)

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

Virangika K Wimalasena (VK)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Yong Kim (Y)

Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Shinjiro Hino (S)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.

Shingo Usuki (S)

Liaison Laboratory Research Promotion Center, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.

Yawara Kawano (Y)

Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.

Mehmet K Samur (MK)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Yu-Tzu Tai (YT)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Nikhil C Munshi (NC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Masao Matsuoka (M)

Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.

Sumio Ohtsuki (S)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Mitsuyoshi Nakao (M)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.

Takashi Minami (T)

Division of Molecular and Vascular Biology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.

Shannon Lauberth (S)

Division of Biological Sciences, University of Califonia, San Diego, La Jolla, California.

Javed Khan (J)

Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Udo Oppermann (U)

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
Structural Genomics Consortium, University of Oxford, Headington, United Kingdom; Oxford Centre for Translational Myeloma Research, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.

Adam D Durbin (AD)

Division of Molecular Oncology, Department of Oncology, and Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.

Kenneth C Anderson (KC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Teru Hideshima (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.

Jun Qi (J)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH